NCT00462423 - Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

January 31, 2012

Conditions

Metastatic Malignant Melanoma

Interventions

DRUG

Avastin

Avastin 10 mg/kg IV every 2 weeks (without rest period).

DRUG

Abraxane

Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.

Trial Locations (2)

The Angeles Clinic and Research Institute, Santa Monica

Northern California Melanoma Center, San Francisco